Murdock David K, Kaliebe Jeff, Overton Naomi
Cardiovascular Associates of Northern Wisconsin, S.C., Wausau, Wisconsin, USA.
Pacing Clin Electrophysiol. 2008 Jun;31(6):765-8. doi: 10.1111/j.1540-8159.2008.01083.x.
Ranolazine is an antianginal agent, which inhibits the abnormal inward Na(+) current and by this inhibition decreases diastolic cardiomyocyte calcium levels and improves electrical stability. Ranolazine has also been shown to be a potent inhibitor of after depolarizations and triggered activity. In this case report, we describe the dramatic antiarrhythmic effects of ranolazine in a patient with nonischemic cardiomyopathy who had malignant ventricular tachycardia. Further research on the antiarrhythmic properties of ranolazine appears warranted.